MedTrace Logo

Association Between Thyroid Dysfunction and Intensive Care Unit Acquired Weaknesss

NCT04313101 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 114

Last updated 2020-03-18

No results posted yet for this study

Summary

Intensive care unit-acquired weakness (ICU-AW) is the most common neuromuscular impairment in critically ill patients. It affects more than 50 % of patients in the intensive care and is related to many problems as difficult weaning from mechanical ventilation, prolonged hospital stay and increased mortality.Thyroid disorders are also associated with neuromuscular abnormalities and may decrease the threshold for the development of any type of myopathy. However, no previous study investigated the direct relationship between thyroid dysfunction and ICUAW.This study aims at evaluation of the association between thyroid dysfunction and intensive care unit acquired weakness.

Conditions

  • Thyroid Abnormalities
  • ICU Acquired Weakness

Interventions

OTHER

withdrawl of blood samples for thyroid function testing

Blood samples will be withdrawn from patients admitted to the intensive care for more than 7 days to measure Thyroid hormones (Free T3: Tri-iodothyronine and Free T4:thyroxine) and TSH ( Thyroid Stimulating Hormone) using ELISA kits. Reference ranges will be as follows: TSH 0.4-4mU/L, Free T3 2-4.4 mU/L, Free T4 0.8-1.9 mU/L. Patients will be then categorized into one of the following categories * Euthyroid ( Normal TSH, FT3 and FT4) * Hyperthyroid (Low TSH) either overt (increased FT3 and /or FT4) or subclinical (normal FT4 and FT3). * Hypothyroid (Elevated TSH) either overt (Low FT3 and FT4) or subclinical (Normal FT3 and FT4) * Non-thyroidal illness syndrome : normal or low TSH in addition to low FT3 ± Low FT4 levels.

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-20
Primary Completion
2020-05-31
Completion
2020-05-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04313101 on ClinicalTrials.gov